This combination would theoretically provide a relatively fast onset of CV benefit (1-3 months) by the SGLT-2 inhibitor with potentially further augmented reductions in MACE exhibited 12 to 18 months later as a result of the GLP-1 RA
Conditions like hypothyroidism, PCOS, and others can impact metabolism and appetite regulation
To model blood levels and steady state across a full titration instead, use the retatrutide half-life calculator
To protect yourself, confirm the exact cancellation method, any deadline relative to your billing cycle, and how renewals work before you enroll - and keep a written record
Will they go low, and go slow
Since most participants did not have chronic health conditions, its also unclear how safe or effective Metabolaid is for those groups